INVO Fertility Inc. (IVF) shares put on quite the show this week, and not necessarily the kind investors enjoy.
The Florida-based fertility clinic operator saw its stock skyrocket 191.73% during Tuesday's regular session, closing at $2.37. But the celebration was short-lived. Shares tumbled 14.78% to $2.02 in after-hours trading, leaving market watchers puzzled about what sparked the dramatic moves in either direction.
No immediate catalyst has emerged to explain the volatility. On January 15, the company participated in the Lytham Partners 2026 Investor Healthcare Summit, where executives discussed performance and industry trends. But that event predated the recent price action by several days.
Expanding Through Acquisition
What we do know is that INVO Fertility has been busy. The company, formerly known as NAYA Biosciences, signed an agreement in December 2025 to acquire Family Beginnings, P.C., an Indiana-based fertility clinic.
The $750,000 deal breaks down as $350,000 in cash at closing (minus a $150,000 holdback) plus $400,000 in Series D nonvoting convertible preferred stock. Family Beginnings brought in roughly $1.2 million in revenue and $200,000 in net income for the twelve months ending September 30, 2025. The transaction should wrap up by February 27.
Revenue Up, Losses Wider
In November 2025, INVO reported third quarter results that showed meaningful top-line growth. Revenue hit $1,757,094, up 23% from $1,433,151 in the same quarter of 2024. Consolidated clinic revenue from the company's Atlanta INVO Center and its Madison, Wisconsin facility climbed 21% to $1,722,223.
The bottom line wasn't as cheerful. The company posted a net loss of $2.6 million, compared to a $1.6 million loss the year before. CEO Steve Shum pointed to "higher patient volume and increased awareness" as growth drivers, even as expenses outpaced revenue gains.
A Stock Trading on the Edge
INVO Fertility carries a market cap of just $5.67 million. The stock trades in an absurdly wide 52-week range of $0.71 to $148.20, reflecting the kind of volatility that makes day traders sweat and long-term investors wince.
The Relative Strength Index sits at 72.66, suggesting the stock might be approaching overbought territory after Tuesday's surge. Over the past year, shares have collapsed 98.25%, a brutal decline that underscores the serious challenges facing the company.
Currently trading just 1.13% above its 52-week low, the stock occupies precarious territory. Any momentum could push it higher, but investors should approach with caution. If recent buying interest evaporates, further downside could materialize quickly.
The technical picture shows short-term upward momentum while medium and long-term trends remain in consolidation. Translation: the stock is bouncing, but whether it's a dead cat or the start of a real recovery remains anyone's guess.
